GLP‐1 agonists were developed as a glucose‐lowering treatment in type 2 diabetes; however, as a class, they are highly efficacious at lowering body weight, leading to FDA approval for the treatment of obesity in the absence of diabetes.74, 75. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.